Lilly Zyprexa IM filing update
Executive Summary
Lilly's Zyprexa (olanzapine) intramuscular NDA filing may be delayed until early 2002, U.S. Operations President Gino Santini indicates during CIBC's healthcare analysts conference in New York City Oct. 5. Lilly had earlier predicted the IM antipsychotic would be launched in the fourth quarter with the sepsis drug Xigris (drotrecogin alfa) (1"The Pink Sheet" Oct. 8, p. 27)...
You may also be interested in...
Lilly Forteo "Approvable": Indications, Manufacturing Issues To Be Resolved
FDA and Lilly are continuing to discuss the appropriate patient populations for the osteoporosis agent Forteo, Lilly CEO Sidney Taurel told analysts Oct. 3.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.